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Purpose: Drug resistance has been recognized to be a major obstacle to the chemotherapy for osteo-
sarcoma. And the potential importance of hypoxia as a target to reverse drug resistance in osteosarcoma
has been indicated, though the mechanism underlining such role is not clariﬁed. The present study aims
to investigate the role of hypoxia in the drug resistance in osteosarcoma cells via activating AMP-acti-
vated protein kinase (AMPK) signaling.
Experimental design: We investigated the promotion of the resistance to doxorubicin of osteosarcoma
MG-63 and U2-os cells in vitro, and then determined the role of hypoxia-inducible factor-1 (HIF-1)α and
HIF-1β, the activation and regulatory role of AMPK in the osteosarcoma U2-os cells which were treated
with doxorubicin under hypoxia.
Results: It was demonstrated that hypoxia signiﬁcantly reduced the sensitivity of MG-63 and U2-os cells
to doxorubicin, indicating an inhibited viability reduction and a reduced apoptosis promotion. And such
reduced sensitivity was not associated with HIF-1α, though it was promoted by hypoxia in U2-os cells.
Interestingly, the AMPK signaling was signiﬁcantly promoted by hypoxia in the doxorubicin-treated U2-
os cells, with a marked upregulation of phosphorylated AMPK (Thr 172) and phosphorylated acetyl-CoA
carboxylase (ACC) (Ser 79), which were sensitive to the AMPK activator, AICAR and the AMPK inhibitor,
Compound C. Moreover, the promoted AMPK activity by AICAR or the downregulated AMPK activity by
Compound C signiﬁcantly reduced or promoted the sensitivity of U2-os cells to doxorubicin.
Conclusion: The present study conﬁrmed the AMPK signaling activation in the doxorubicin-treated os-
teosarcoma cells, in response to hypoxia, and the chemical upregulation or downregulation of AMPK
signaling reduced or increased the chemo-sensitivity of osteosarcoma U2-os cells in vitro. Our study
implies that AMPK inhibition might be a effective strategy to sensitize osteocarcoma cells to che-
motherapy.
& 2016 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Osteosarcoma is the most frequent primary bone malignancy,
mainly attacks adolescents [1]. The combined chemotherapy with
intensive dose has greatly improved the overall survival for os-
teosarcoma patients to over 70% [2]. However, the prognosis re-
mains poor for those with metastasis, or for those who relapse,
and survival rates only reach 20–30% [3,4]. Doxorubicin, metho-
trexate and Cisplatin are commonly used as anticancer drugs in
osteosarcoma [5] for the last 20 years, and there has been no
improvement in the survival of those osteosarcoma patients, who
acquisite the drug-resistant phenotype. Thus, it is urgent to re-
cognize the drug-resistance mechanism of osteosarcoma and toGmbH. This is an open access artprovide novel therapeutic options for this disease.
Hypoxia-induced drug resistance has been conﬁrmed for a
variety of anti-tumor agents in various types of tumors [8,6,7], and
even in osteosarcoma [9]. Such hypoxia markers as hypoxia-in-
ducible factor-1 (HIF-1), vascular endothelial growth factor (VEGF)
and carbonic anhydrase IX (CA IX) are detectable in osteosarcomas
[10], and correlate with poor progress of osteosarcoma patients,
suggesting the important role of hypoxia in the survival of os-
teosarcoma cells [11,12], and implying the potential importance of
hypoxia as a target to antagonize drug resistance in osteosarcoma.
However, it is indicated that the drug resistance in osteosarcoma is
independent on the upregulated HIF-1α, suggesting other hypox-
ia-related signaling may be more relevant in the drug resistance to
osteosarcoma.
Multiple other signaling pathways are deregulated in hypoxia
and may exert regulatory roles in the hypoxia-induced drug re-
sistance. Wild-type p53 is conﬁrmed to be inactivated in someicle under the CC BY-NC-ND license
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Phosphoinositol-3-kinase (PI3K) pathway and nuclear factor kap-
pa-B (NF-κB) have also been indicated to involve in the hypoxia-
induced drug resistance, mainly by inhibiting the drug-induced
apoptosis [16,15,17]. And the target inhibiting of these signaling
pathways sensitizes cells to cytotoxic agents under the condition
of hypoxia, implying these markers as possible targets to coun-
teract the hypoxia-induced drug resistance.
AMP-activated protein kinase (AMPK) is the most important
sensor of cellular energy [19,18], and is also activated by hypoxia
as a compensatory response to the reduced mitochondrial re-
spiration [20]. The heterotrimeric AMPK composes of two reg-
ulatory subunits and one catalytic subunit, which is activated the
increased AMP/ATP ratio [21]. Then the activity was promoted of
upstream kinases and phosphatases that control AMPK phos-
phorylation and dephosphorylation at the Thr-172 [22,23], parti-
cularly by the tumor suppressor LKB1, which phosphorylates the
catalytic subunit of AMPK in an AMP-dependent manner [24,25].
AMPK is also activated by the Ca2 /calmodulin-dependent protein
kinase kinase (CaMKK) [27,26], independently of cellular AMP le-
vels. In addition, the activation of AMPK can also be induced in
response to oxidant stress [28,29] with or without hypoxia.
However, the role of the AMPK activation in hypoxia in osteo-
sarcoma is still unclariﬁed.
In the current study, we investigated the resistance of osteo-
sarcoma cells to the widely utilized in clinic cytotoxic drug, dox-
orubicin under hypoxia, and then examined the association of
such resistance with the activation of AMPK signaling. On the
other side, we investigated the inﬂuence by the chemical inhibi-
tion of AMPK signaling on the hypoxia-induced resistance to
doxorubicin. The present study indicated the key regulatory role of
AMPK in the hypoxia-induced resistance to doxorubicin in osteo-
sarcoma cells, suggesting a possible target of AMPK against the
drug-resistance of osteosarcoma cells.2. Materials and methods
2.1. Cell culture and treatment
Human osteosarcoma cell line MG-63 and U2-os were pur-
chased from American Type Culture Collection (ATCC) (Rockville,
MD, USA). MG-63 cells were cultured in Eagle's minimal essential
medium (EMEM), supplemented with 2 mM Glutamine, 1% Non
Essential Amino Acids (NEAA) and 10% Fetal bovine serum (FBS)
(Invitrogen, Carlsbad, CA, USA), and were routinely incubated at
37 °C with 5% CO2. U2-os cells were grown in RPMI-1640 medium
(Ameresco, Framingham, MA, USA) supplemented with 10% FBS
(Invitrogen, Carlsbad, CA, USA). For hypoxia culture, MG-63 or U2-
os cells were incubated in a hypoxia incubator infused with a gas
mixture of 5% CO2, 2% oxygen and nitrogen, whereas cells were
incubated in an ordinary incubator with 5% CO2. For the doxor-
ubicin treatment, MG-63 or U2-os cells with more than 85% con-
ﬂuence were updated with medium containing 2% FBS and the
docorubicin with various concentrations. To induce or inhibit the
AMPK activity, AICAR and Compound C (Sigma-Aldrich, St. Louis,
MO, USA) were added to the medium with a concentration of
1 mM and 20 μM respectively.
2.2. MTT assay and apoptosis assay
The viability of MG-63 or U2-os cells which were seeded in 96-
well plates with more than 85% conﬂuence post various treat-
ments were measured with MTT assay according to the standard
protocol. The absorbance was measured at 570 nm with areference wavelength of 750 nm using a spectrophotometer.
Apoptosis of U2-os cells was examined with an Annexin V-FITC
apoptosis detection kit (Sigma-Aldrich, USA). Brieﬂy, 6105 U2-os
cells were stained with Annexin V-FITC and propidium iodide and
then were detected by a FACScan ﬂow cytometer (Bio-Rad, Her-
cules, CA, USA). The results were presented as a percentage of
apoptotic cells from total cells.
2.3. Western blot analysis
U2-os cells, post treatment, were harvested and were homo-
genized in an ice-cold Cell lysis buffer (Bio-Rad, Hercules, CA,
USA). Cellular lysates was centrifugated with 12,000 g for 30 min
at 4 °C, and the supernatant was collected. Protein samples were
separated with 8–12% SDS-PAGE gel and were transferred to a
nitrocellulose membrane (Millipore, Bedford, MA, USA). The
membrane was blocked for non-speciﬁc binding targets with 5%
Skimmed milk powder overnight at 4 °C, and were incubated with
the rabbit polyclone antibody (against caspase 3, Poly (ADP-ribose)
polymerase (PARP), HIF-1α, HIF-1β, AMPKα with or without
phoshorylated Thr 172, ACC with or without phoshorylated Ser 79,
or β-actin) overnight at 4 °C, and then were incubated with HRP-
linked secondary anti-rabbit antibody (New England Biolab, Ips-
wich, UK) for 1 h at room temperature. The speciﬁc binding band
was scanned and quantiﬁed according to the band density by
Image J software.
2.4. HIF-1α knockdown via RNA interference
The HIF-1α speciﬁc siRNA (siRNA- HIF-1α) (25 or 50 nM) or the
scrambler oligonucleotides as control (siRNA-Con) (25 or 50 nM)
were purchased from Thermo Fisher (Waltham, MA, USA), and
were transfected into U2-os cells with Opti-MEM containing Li-
pofectamine RNAiMax (Invitrogen, Carlsbad, CA, USA). 6 h post
transfection, cells were updated with fresh RPMI-1640 medium,
which was supplemented with 2% FBS, and were subject to other
treatment or were assayed for the knockdown efﬁciency post
another inoculation of 24 h.
2.5. DCFH-DA assay ELISA for AMPK activity
Reactive oxygen species (ROS) was assessed using 2,7-di-
chloroﬂuorescin diacetate (DCFH-DA). U2-os cells were added
with BSS containing DCFH-DA (5 mM), and ﬂuorescence signaling
was collected at 535 nm using excitation at 484 nm. Cellular
ﬂuorescence density from individual cell well was collected and
was averaged to provide an overall assessment for each group.
The AMPK activity was examined with AMPK Kinase Assay Kit
AMPK Kinase Assay Kit (CY-1182; CycLex, Nagano, Japan) accord-
ing to the manufacturer’s manual. U2-os cells post various treat-
ments were directly lysed with ice-cold lysis buffer; then the
cellular lysates were serially diluted in Kinase buffer and supple-
mented with phosohorylation substrate, and the amount of
phosphorylated substrate speciﬁcally bonded to an anti-phospho-
mouse IgG, which then assayed with anti mouse Ig-G conjugated
with horseradish peroxidase and its substrate, by absorbance
450 nm.
2.6. Statistical evaluations
Quantitative results are presented as mean7SE. For the ana-
lysis between two groups, the Student’s t test was performed. A p
value less than 0.05 was considered signiﬁcant.
Fig. 1. Hypoxia reduces the sensitivity of osteosarcoma cells to doxorubicin in vitro. A: Viability of MG-63 cells, post a 24 h pre-treatment incubation in normoxia or hypoxia,
and subject to the treatment with doxorubicin of 0, 2, 4, 8, or 16 μM for 2 h. MTT assay was performed post another 48 h inoculation; B: Viability of U2-os cells, post a 24 h
pre-treatment incubation in normoxia or hypoxia, and subject to the treatment with doxorubicin of 0, 5, 10, 20, or 40 μM for 2 h. MTT assay was performed post another 24 h
inoculation; C: Apoptosis induction in U2-os cells post a 24 h pre-treatment incubation in normoxia or hypoxia, and after an exposure to a 2 h treatment with doxorubicin (5,
10 or 20 μM); D: Western blot analysis of cleaved caspase 3 (c casp 3) and lyzed PARP (L PARP) in U2-os cells post the hypoxia and the treatment with 20 μM doxorubicin. E
and F: Relative c casp 3 or L PARP level in U2-os cells post the hypoxia and the treatment with 20 μM doxorubicin. Experiments were repeated independently in triplicate.
*po0.05, **po0.01, ***po0.001, ns: no signiﬁcance.
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3.1. Hypoxia reduces the sensitivity of osteosarcoma cells to doxor-
ubicin in vitro
We ﬁrstly examined the viability of doxorubicin-treated os-
teosarcoma MG-63 cells under normoxia or hypoxia. It was shown
in Fig. 1A, that the doxorubicin with 4, 8 or 16 μM signiﬁcantly
reduced the viability of MG-63 cells under normoxia (po0.01 or
po0.001). Interestingly, the cellular viability reduction in the MG-
63 cells under hypoxia was signiﬁcantly less than in the cells un-
der normoxia (po0.05 respectively for 4, 8 or 16 μM). Then we
reevaluated such regulation by hypoxia in U2-os osteosarcomacells. Fig. 1B also indicated that the doxorubicin treatment with 5,
10, 20 or 40 μM signiﬁcantly reduced the cellular viability
(po0.05, po0.01 or po0.001). And the hypoxia pre-treatment
could signiﬁcantly ameliorate such viability reduction in U2-os
cells (po0.05 for 5 μM, po0.01 respectively for 10, 20 or 40 μM).
Moreover, to reconﬁrm the inﬂuence by hypoxia on the doxor-
ubicin sensitivity of osteosarcoma cells, we determined the
apoptosis induction in U2-os cells treated with doxorubicin under
normoxia or hypoxia. It was indicated that less apoptotic U2-os
cells were induced by the doxorubicin with 10 or 20 μM in the
hypoxia group (Fig. 1C; po0.05 respectively).
In addition, we analyzed the activation of caspase 3, which is
the executive marker of apoptosis [30], in the doxorubicin-treated
Fig. 2. Hypoxia-induced chemo-resistance is HIF-1-independent in U2-os cells. A–C: Western blot analysis of HIF-1α and HIF-1β in U2-os cells with the pre-incubation in
normoxia or hypoxia for 6, 12 or 24 h and the doxorubicin treatment with 20 μM for 2 h, the level of HIF-1α or HIF-1β was relative to β-actin; D–F: Western blot analysis of
HIF-1α, cleaved caspase 3 and lyzed PARP, in U2-os cells post the transfection with 20 or 50 nM siRNA- HIF-1α or control siRNA, with β-actin as internal control; G and H:
Viability reduction and apoptosis induction of U2-os cells post the transfection with 20 or 50 nM siRNA- HIF-1α or control siRNA, via MTT assay and FACScan ﬂow assay. Each
result was averaged for triple independent experiments. **po0.01, ***po0.001, ns: no signiﬁcance.
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the cleaved caspase 3 (activated form) was markedly lower in the
U2-os cells under hypoxia (po0.01 respectively). And the sub-
strate of caspase 3, Poly ADP ribose polymerase (PARP) was alsomarkedly less lyzed in the U2-os cells under hypoxia (Fig. 1F;
po0.05 respectively for 10, 20 or 40 μM). Therefore, hypoxia re-
duces the sensitivity of osteosarcoma cells to doxorubicin in either
MG-63 or U2-os osteosarcoma cells.
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osteosarcoma cells to doxorubicin
HIF-1α is the best characterized marker for hypoxia and is
sensitively accumulated under hypoxia [32,31]. To investigate a
possible regulatory role of HIF-1α on the sensitivity of osteo-
sarcoma cells to doxorubicin, we then quantiﬁed the level of HIF-
1α and the constitutive HIF-1β in the doxorubicin-treated U2-os
cells with or without hypoxia. The western blotting results de-
monstrated that the HIF-1α level was dramatically promoted by
hypoxia in the doxorubicin-treated U2-os cells (Figs. 2A and 1B;
po0.01 or po0.001) at 6, 12 or 24 h post inoculation. However,Fig. 3. Hypoxia induces AMPK signaling in U2-os cells, which are sensitive to the AMPK a
the inoculation under hypoxia or normoxia for 3, 6, 12 or 24 h and the doxorubicin treat
phosphorylation, of ACC with or without Ser 79 phosphorylation in the U2-os cells succes
C or 1 mM AICAR for 24 h and the doxorubicin treatment with 20 μM for 2 h; E: Relativel
Compound C) for 24 h and the doxorubicin treatment with 20 μM for 2 h. Experimentsthere was no marked difference in the HIF-1β level between the
hypoxia and normoxia groups (Fig. 2C). Then the siRNA targeting
HIF-1α was used to knockdown the expression of HIF-1α and re-
evaluated the inﬂuence of hypoxia on the drug resistance. Fig. 2D
and E conﬁrmed the signiﬁcant blockage of the HIF-1α induction
by hypoxia in U2-os cells (po0.01 respectively). However, cleaved
caspase 3 and lyzed PARP were not signiﬁcantly downregulated by
the HIF-1α blockage (Fig. 2F); and the cellular viability (Fig. 2G)
and the apoptosis (Fig. 2H) induction were also not regulated by
the HIF-1α blockage. Thus, we deduced that the reduced drug
sensitivity of U2-os cells under hypoxia was not associated with
HIF-1α.ctivator and inhibitor. A: Reactive oxygen species (ROS) level in the U2-os cells post
ment with 20 μM for 2 hs; B–D: Western blotting of AMPK with or without Thr 172
sively post the inoculation under hypoxia and the treatment with 20 μM Compound
AMPK activity in the combined treatment with hypoxia and 1 mM AICAR (or 20 μM
were repeated in triplicate. *po0.05, **po0.01, ***po0.001, ns: no signiﬁcance.
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in the presence of doxorubicin
It has been conceived that the oxygen deprivation under hy-
poxia upregulates the production of reactive oxygen species (ROS),
which then triggers the AMPK activation, but independent of an
increase in AMP/ATP ratio [34,33]. We then determined the acti-
vation of AMPK signaling under hypoxia in U2-os cells and ex-
amined the role of AMPK activation in drug sensitivity of U2-os
osteosarcoma cells. It was indicated that the U2-os cells under
hypoxia produced markedly increased ROS (Fig. 3A; po0.05,
po0.01 or po0.001) via the DCFH-DA ﬂuorescence assay. And the
western blot analysis demonstrated that the levels of phosphory-
lated AMPK and phosphorylated ACC, both of which are the active
forms of AMPK signaling, were signiﬁcantly promoted in the U2-os
cells under hypoxia for 6 or 12 h (Fig. 3B–D; whichever in theFig. 4. Manipulation of AMPK activity with the AMPK activator or inhibitor exerts inﬂ
treatment with 1 mM AICAR or 20 μM Compound C on the viability of U2-os cells unde
western blot analysis of cleaved caspase 3 and lyzed PARP (D) in the U2-os cells post the t
the doxorubicin treatment with 20 μM for 2 h; E and F: Relative levels of cleaved caspase
treatment with 1 mM AICAR or 20 μM Compound C. Results were averaged for triple inpresence of AMPK activator, AICAR, or AMPK inhibitor, Compound
C; po0.05 or po0.01). Moreover, the levels of phosphorylated
AMPK and phosphorylated ACC was markedly up-regulated by the
AMPK activator, AICAR, or downregulated by AMPK inhibitor,
Compound C (po0.01 or po0.001); and the AMPK activity assay
also indicated the signiﬁcant promotion of AMPK signaling by
hypoxia, and the marked up- or down-regulation of AMPK sig-
naling by AICAR or Compound C (Fig. 3E; po0.05, po0.01 or
po0.001).
3.4. Chemical manipulation of AMPK signaling regulates the sensi-
tivity of osteosarcoma cells to doxorubicin
Then we examined the inﬂuence of AMPK activation on the U2-
os cell sensitivity to doxorubicin. Fig. 4A indicated that the pro-
motion by AICAR and the reduction by Compound C of the viabilityuence on the sensitivity of U2-os cells to doxorubicin. A and B: Inﬂuence of the
r normoxia (A) or hypoxia (B) for 24 or 48 h; C and D: Apoptosis induction (C) and
reatment with 1 mM AICAR or 20 μM Compound C under hypoxia for 24 or 48 h and
3 (E) or lyzed PARP (F) to β-actin in the hypoxia-treated U2-os cells post the post the
dependent experiments. *po0.05, **po0.01, ns: no signiﬁcance.
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under hypoxia of the cellular viability promotion by AICAR and the
reduction by Compound C (Fig. 4B; po0.05 respectively). And the
apoptosis level was also signiﬁcantly regulated by both chemical
agents (reduced by AICAR, whereas promoted by Compound C;
Fig. 4C; po0.05 or po0.01) in the U2-os cells under hypoxia. In
addition, levels of cleaved caspase 3 and the lyzed PARP were also
reduced by the treatment with AICAR, whereas were upregulated
by Compound C (Fig. 4D–F; po0.05 or po0.01). Thus, we con-
ﬁrmed that AMPK signaling was promoted by the hypoxia-medi-
ated resistance of U2-os cells to doxorubicin.4. Discussion
The role of hypoxia in the drug sensitivity has not been uni-
versally concluded, varying according to the type of tumor and the
drug used [35,36]. It was observed to be resistant in rhabdomyo-
sarcoma, Ewing’s sarcoma and neuroblastoma [36,37]. Evidence
exists of the importance of hypoxia in osteosarcoma [39,38]. In
particular, the patients with a moderate or strong expression of
HIF-1α showed signiﬁcantly shorter overall survival (OS) and
disease-free survival (DFS), compared with HIF-1α negative/weak
expression [40]. And recently, a signiﬁcant hypoxia-induced drug
resistance in osteosarcoma cells has been conﬁrmed in intro [9],
highlighting the potential importance of hypoxia in the drug re-
sistance in osteosarcoma. However, though the HIF-1α was also
found to be upregulated by hypoxia, it was irrelevant to such drug
resistance.
In the present study, we ﬁrstly conﬁrmed the resistance of
osteosarcoma U2OS cells to doxorubicin under hypoxia via in-
hibiting the drug-induced apoptosis. The hypoxia pre-treatment
could signiﬁcantly ameliorate the viability reduction in U2-os cells
which were treated with doxorubicin with 5, 10, 20 or 40 μM. And
less apoptotic U2-os cells were induced, and less cleaved caspase
(activated form) and less lyzed PARP were promoted by the dox-
orubicin treatment in the hypoxia group. Therefore, hypoxia re-
duces the sensitivity of osteosarcoma cells to doxorubicin in either
MG-63 or U2-os osteosarcoma cells. Then we investigated the role
of HIF-1α, which is the best characterized marker for hypoxia
[32,31], in the hypoxia-mediated resistance of U2-os cells to
doxorubicin. Interestingly, HIF-1α was signiﬁcantly promoted by
hypoxia in U2-os cells which were treated with doxorubicin,
whereas exerted no inﬂuence on the sensitivity of U2-os cells to
doxorubicin.
Reactive oxygen species (ROS) has been conceived to be pro-
moted under hypoxia and to trigger the AMPK activation, in-
dependent of an increase in AMP/ATP ratio [34,33]. In the present
study, we also conﬁrmed the activation of AMPK by hypoxia in U2-
os cells. Markedly increased ROS was indicated in the U2-os cells
under hypoxia. And signiﬁcantly upregulated levels of phos-
phorylated AMPK and phosphorylated ACC, both of which are the
active forms of AMPK signaling, were also promoted in the U2-os
cells under hypoxia. And the levels of phosphorylated AMPK and
phosphorylated ACC were signiﬁcantly up-regulated by the AMPK
activator, AICAR, or downregulated by AMPK inhibitor, Compound
C in the doxorubicin-treated U2-os cells. Moreover, AMPK signal-
ing has been recognized to involve in the hypoxia-mediated drug
resistance in several types of cancers, such as non–small cell lung
cancers to cisplatin and doxorubicin [41], prostate cancers [42].
However, there was a controversy about the activation of AMPK
signaling in the drug resistance. AMPK is activated in the prostate
cancer cells [42], while is inactivated in the lung cancer cells [41],
during hypoxia leading to drug resistance, implying a cancer type-
dependence. And the present study also conﬁrmed the activation
of AMPK signaling during the hypoxia-induced drug resistance inosteosarcoma cells. The chemical manipulation of AMPK signaling
regulates the sensitivity of osteosarcoma cells to doxorubicin. The
promotion by AICAR and the reduction by Compound C to the
AMPK signaling signiﬁcantly ameliorated or deteriorated the via-
bility reduction or apoptosis induction of U2-os cells under hy-
poxia. In addition, the level of cleaved caspase 3 and the lyzed
PARP were also reduced by the treatment with AICAR, whereas
were upregulated by Compound C. Thus, the AMPK signaling
mediated the hypoxia-induced resistance of U2-os cells to
doxorubicin.
Autophagy is a dynamic self-degradation process for cellular
components by cellular lysosome under a stringent regulation
[43,44], and has also been recognized during ischemic heart dis-
ease [45]. Autophagy normally maintains at a low level in heart,
and is sharply promoted as a response to such environmental
stress conditions as ATP depletion, excessive ROS and mitochon-
drial dysfunction [46,47]. Moreover, autophagy has been identiﬁed
to mediate the hypoxia-induced resistance by regulating the an-
giogenesis in malignancies [48]. The present study has recognized
the involvement of autophagy in the hypoxia-induced resistance
in osteosarcoma cells. However, it is not clear about the orche-
strated pathways about AMPK signaling and autophagy promotion
during the hypoxia-induced resistance. The reduced adenosine-
triphosphate (ATP) has been recognized to activate autophay [49].
The increased AMP/ATP ratio activates AMP-activated protein ki-
nase (AMPK) [50], which successively induces autophagy via in-
hibiting mammalian target of rapamycin (mTOR) [46]. The pro-
moted reactive oxygen species (ROS) has also been recognized to
induce autophagy in cardiocytes [51], in choriocarcinoma cells
[52], and in breast cancer cells [53]. Therefore, the role of autop-
hagy in the AMPK-mediated chemoresistance of osteocarcoma
cells needs to be further clariﬁed.5. Conclusion
The present study conﬁrmed the hypoxia induced resistance of
osteocarcoma cells to doxorubicin, and such chemo-resistance was
HIF-1α-independent. Moreover, we recognized the involvement to
AMPK signaling in such hypoxia-induced chemoresistance in U2-
os osteocarcoma cells, chemical manipulation of AMPK activity
exerted an inﬂuence of such chemoresistance in U2-os osteo-
carcoma cells. Our study implies that AMPK inhibition might be a
effective strategy to sensitize osteocarcoma cells to chemotherapy.Conﬂict of interest
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